IMMUNEERING CORP. news, videos and press releases
For more news please use our advanced search feature.
IMMUNEERING CORP. - More news...
IMMUNEERING CORP. - More news...
- Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
- Immuneering Corporation Announces Grant of Inducement Award
- Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
- Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
- Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
- Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
- Immuneering Launches Pancreatic Cancer Advisory Board
- Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
- Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
- Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
- Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
- Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
- Immuneering to Present at the Jefferies Global Healthcare Conference
- Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Recognizes Melanoma Awareness Month
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
- Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
- Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
- Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
- Immuneering to Participate in the Cowen 44th Annual Health Care Conference
- Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
